Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTIGE: adjuvant nivolumab + ipilimumab versus standard postoperative chemotherapy after resection of high-risk gastric or gastroesophageal junction adenocarcinoma
MOH_2019-02-26_003681Phase 2Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2019-02-26_003681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-26_003681.